EMA Validation of ENHERTU Breast Cancer Treatme...

By HEOR Staff Writer

February 20, 2026

EMA Validates ENHERTU Breast Cancer Treatment Variation The European Medicines Agency (EMA) has validated a Type II Variation marketing authorization application for ENHERTU br...
European Commission Approves Enhanced Wegovy Obesity Treatment Dose
Genotype ECG Prediction
NICE Endorses Pegzilarginase for Treating Arginase Deficiency
Late-Breaking Data on Bladder Cancer Treatments from KEYNOTE-B15 Trial
AstraZeneca Financial Results: Strong Revenue Growth and Pipeline Expansion i...
KEYTRUDA Ovarian Cancer Treatments: FDA Approves New Regimens for Platinum-Re...
National HealthTech Access: Transforming NHS Adoption and Equity
Datroway Metastatic Breast Cancer: FDA Grants Priority Review for Breakthroug...
FDA Confirms GLP-1 RA Safety Review: No Increased Suicidal Risk
CHMP January 2026 Approvals: Expanding Access to Innovative Therapies
Accelerating FAST-EU Clinical Trials
Alzheimer’s Care Innovation: Advancing Implementation Across Europe